Traitements hormonaux de la ménopause et risques de cancers

Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Beral, 2003, Breast cancer and hormone-replacement in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14596-5 Cogliano, 2005, Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment, Lancet Oncol, 6, 552, 10.1016/S1470-2045(05)70273-4 IARC. Monographs on the evaluation of carcinogenic risks to humans. 2012; 100(A). http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A.pdf Fournier, 2009, Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?, J Clin Oncol, 27, 5138, 10.1200/JCO.2008.21.6432 Fournier, 2014, Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Res Treat, 145, 535, 10.1007/s10549-014-2934-6 Cordina-Duverger, 2013, Risk of breast cancer by type of menopausal hormone therapy: a case-control study among postmenopausal women in France, PLoS One, 8, e78016, 10.1371/journal.pone.0078016 Beral, 2011, Breast cancer risk in relation to the interval between menopause and starting hormone therapy, JNCI, 103, 296, 10.1093/jnci/djq527 Furness, 2012, Hormone therapy in postmenopausal women and risk of endometrial hyperplasia, Cochrane Database Syst Rev, 8, CD000402 Brinton, 2014, Menopausal hormone therapy and risk of endometrial cancer, J Steroid Biochem Mol Biol, 142, 83, 10.1016/j.jsbmb.2013.05.001 Fournier, 2014, Risk of endometrial cancer associated with different hormone-replacement therapies in the E3N cohort, 1992–2008, Am J Epidemiol, 80, 508, 10.1093/aje/kwu146 Beral, 2015, Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies, Lancet, 385, 1835, 10.1016/S0140-6736(14)61687-1 Lin, 2012, The effect of estrogen vs. combined estrogen-progesteron therapy on the risk of colorectal cancer, Int J Cancer, 130, 419, 10.1002/ijc.26026 Chlebowski, 2014, Menopausal hormone therapy and cancer: changing clinical observations of target site specificity, Steroids, 90, 53, 10.1016/j.steroids.2014.06.001 Séradour, 2009, Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006, Bull Cancer, 96, E1 Fournier, 2011, Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts, Menopause, 18, 219, 10.1097/gme.0b013e3181ecf3ec Canonico, 2007, Hormone therapy and venous thromboembolism among postmenopausal women. Impact of route of estrogen administration and progestogens: the ESTHER study, Circulation, 115, 840, 10.1161/CIRCULATIONAHA.106.642280 Fournier, 2014, Health characteristics of women beginning postmenopausal hormone therapy: have they changed since the publication of the Women's Health Initiative?, Menopause, 21, 687, 10.1097/GME.0000000000000159